Mantle Cell Lymphoma (MCL), POZ
Conditions
Brief summary
This multicenter trial evaluates the efficacy and safety of pomalidomide combined with orelabrutinib and zuberitamab (POZ) in patients with mantle cell lymphoma (MCL). After six cycles of POZ, patients who achieved minimal residual disease (MRD) negativity received maintenance therapy with orelabrutinib plus zuberitamab for up to 18 cycles. Those with MRD positivity were excluded and received alternative treatments. The primary endpoint is the MRD rate after six cycles of POZ. Secondary endpoints include progression-free survival (PFS), overall survival (OS), MRD rate, objective response rate (ORR), and safety.
Interventions
DRUGPomalidomide
4mg/day PO once daily, day1-21/cycle
DRUGOrelabrutinib
150mg/day PO once daily
DRUGZuberitamab
375 mg/m² IV on day 1/cycle
Sponsors
Peking University Third Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Pathologically confirmed mantle cell lymphoma * Age 18-80 years, both genders are eligible.. * Untreated MCL. * At least one measurable lesion. Measurable disease is defined as a tumor mass measurable in one or two dimensions ≥1.5 cm, as well as measurable spleen lesions. * Any one of the following factors is present:: MIPI intermediate-high risk, ki67≥30%, blastoid/pleomorphic, TP53 abnormality (mutation/deletion) or p53 protein expression \>50%, large mass (maximum diameter ≥7.5cm), complex karyotype (≥3 chromosomal abnormalities (excluding t(11; 14))) * Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2. * Hematologic function is adequate, defined as: 1. Absolute neutrophil count (ANC) ≥1×109/L, growth factor support must not be used within 7 days prior to testing; 2. Platelet count ≥75×10⁹/L, or ≥50×10⁹/L (if bone marrow involvement), no use of growth factor support or transfusion allowed within 7 days prior to testing. * Adequate hepatic function per local laboratory reference range as follow: 1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5× the upper limit of normal (ULN); 2. Bilirubin ≤ 2 × ULN (except for those diagnosed with Gilbert's syndrome, which allows up to 5 × ULN) * Adequate renal function as demonstrated by: 1. Creatinine clearance ≥60 mL/min (estimated using the Cockcroft-Gault formula or the glomerular filtration rate \[eGFR\] estimated using the Modification of Diet in Renal Disease \[MDRD\] formula) 2. Serum creatinine ≤1.5×ULN * International Normalized Ratio (INR) ≤ 1.5 × ULN and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN * Life expectancy of more than 3 months. * Ability to provide written informed consent and understand and comply with study requirements. * Able to comply with the study visit schedule and other protocol requirements
Exclusion criteria
* Current central nervous system involvement or suspected patients and those with a history of this condition * Previously received systemic treatment for MCL, including BTKi. * Uncontrolled active systemic fungal, bacterial, or viral infections (defined as persistent signs/symptoms related to the infection despite the use of appropriate antibiotics, antiviral therapy, and/or other treatments with no improvement). * Known human immunodeficiency virus (HIV) infection, or the following serological status indicating active hepatitis B or C virus infection: 1. Subjects with positive hepatitis B virus core antibody (HBcAb) and negative surface antigen (HBsAg) must have a negative polymerase chain reaction (PCR) result prior to the first dose. Subjects with positive HBsAg or HBV-DNA: 2. Subjects with positive hepatitis C antibodies must have an HCV-RNA negative result before the first dose. Subjects with positive hepatitis C PCR results will not be eligible for this study. * Clinically severe cardiovascular diseases, including: 1. Myocardial infarction occurring within the 6 months prior to screening; 2. Unstable angina occurring within 3 months prior to screening; 3. Clinically significant arrhythmias (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes ventricular tachycardia); 4. QTcF (corrected by Fridericia's formula) \> 480 msec; 5. History of second-degree type II atrioventricular (AV) conduction block or third-degree atrioventricular conduction block; 6. III or IV congestive heart failure as defined by the New York Heart Association (NYHA) * History of severe hemorrhagic disorders, such as hemophilia A, hemophilia B, von Willebrand disease, or a history of spontaneous bleeding requiring blood transfusion or other medical interventions. * History of deep vein thrombosis (DVT) or pulmonary embolism (PE) in the past 12 months * History of significant cerebrovascular disease/events within 6 months prior to the first administration of the investigational drug, including stroke or intracranial hemorrhage. * Unable to swallow capsules or having significant gastrointestinal functional disorders, such as malabsorption syndrome, gastric or small intestine resection, symptomatic inflammatory bowel disease, or partial or complete intestinal obstruction. * Continuous treatment with strong and moderate CYP3A inhibitors or CYP3A inducers is required. If the patient has taken strong or moderate CYP3A inhibitors or inducers within 7 days prior to the first dose of the investigational drug (or has taken these drugs for less than 5 half-lives), they cannot be enrolled. Patients using moderate CYP3A inhibitors can be considered for the study after at least a 7-day washout period. * Anticoagulation treatment with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon) is required within 7 days after the first dose of the investigational drug or receiving anticoagulation therapy. * Pregnant or breastfeeding women * Hypersensitivity to any investigational drug * Any mental or cognitive impairment that may limit their understanding, execution, and compliance with the informed consent form and the study. * Subjects with drug abuse and alcoholism
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Minimum residual disease (MRD) rate | 6 months | After 6 cycles of the pomalidomide combined with orelabrutinib and zuberitamab (POZ) regimen, the proportion of patients with undetectable minimal residual disease (MRD) (≤10-5) as evaluated by the high-throughput sequencing (NGS) platform. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| MRD rate | 3 months | The proportion of patients with undetectable minimal residual disease (MRD) (≤10-5) as evaluated by the high-throughput sequencing (NGS) platform. |
| Overall Response Rate | up to 3 years | Percentage of participants with overall response was determined on the basis of investigator assessments according to 2014 Lugano criteria. |
| Progression-free survival | up to 3 years | Progression-free survival was defined as the time from the date of randomization until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first. |
| Overall survival | up to 3 years | Overall survival was defined as the time from the date of randomization to the date of death from any cause. |
Countries
China
Contacts
Primary ContactHongmei Jing
Outcome results
None listed